Clinical phenotypes and evolution of AD are closely associated with tau density and spatial distribution of hyperphosphorylated tau [as measured by [18F]AV-1451], which are correlated with the degree of neurodegeneration and syndrome localization (14). This evidence concerns the gene MAPT and Alzheimer disease.